Avalo Therapeutics (AVTX) Change in Acquisitions & Divestments (2025 - 2026)
Avalo Therapeutics (AVTX) posted Change in Acquisitions & Divestments of $25.5 million for Q1 2026, up 18.63% on a QoQ basis from $21.5 million in Q4 2025.
Avalo Therapeutics (AVTX) Change in Acquisitions & Divestments (2025 - 2026) Analysis & Trends
Avalo Therapeutics' Change in Acquisitions & Divestments history runs 2 years deep, the most recent figure standing at $25.5 million for Q1 2026.
- Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.0 million (changed N/A YoY) and the FY2025 annual result came in at $32.0 million, changed N/A from the prior year.
- Change in Acquisitions & Divestments was $25.5 million for Q1 2026 at Avalo Therapeutics, up from $21.5 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $25.5 million in Q1 2026 and bottomed at $21.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 396.31 Mn | 339.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.51 Mn |
| Mar 31, 2026 | 25.51 Mn |
| Dec 31, 2025 | 21.50 Mn |
| Dec 31, 2025 | 21.50 Mn |